Benzodiazepinler ve Yeni Tasarım Benzodiazepinler
Özet
Benzodiazepinler, santral sinir sisteminde GABA_{A} reseptörlerinin GABA’ya afinitesini artıran allosterik modülatörler olup anksiyolitik, hipnosedatif, kas gevşetici ve antikonvülzan etkileri nedeniyle geniş bir klinik kullanım alanına sahiptir. Karaciğerde mikrozomal oksidasyon (Faz I) ve glukuronidasyon (Faz II) reaksiyonlarıyla metabolize edilen bu ilaçlar; etki sürelerine göre çok kısa, kısa, orta ve uzun etkili olarak sınıflandırılır. Benzodiazepinler yüksek terapötik indekslerine rağmen uzun süreli kullanımlarda fiziksel ve psikolojik bağımlılık, tolerans ve şiddetli yoksunluk semptomlarına yol açabilirler. Türkiye'de yeşil reçeteye tabi olmalarına karşın suistimal edilme potansiyelleri yüksektir. Son yıllarda sanal ilaç pazarında "tasarım benzodiazepinler" veya "araştırma kimyasalları" adıyla ruhsatsız olarak satılan fenazepam, etizolam ve flubromazepam gibi yeni psikoaktif maddeler (NPS) ortaya çıkmıştır. Bu yeni bileşikler, özellikle opioid veya alkol ile birlikte alındığında ölümcül solunum depresyonu ve koma riskini belirgin şekilde artırarak halk sağlığını tehdit etmektedir. Biyolojik örneklerde immunoassay yöntemleriyle yapılan taramalarda sertralin veya efavirenz gibi ilaçlar nedeniyle yanlış pozitif ya da düşük konsantrasyonlar nedeniyle yanlış negatif sonuçlar görülebildiğinden, LC-MS ve GC-MS gibi kromatografik doğrulama yöntemlerinin ve adli-klinik toksikolojik analizlerin uygulanması kritik önem taşımaktadır.
Referanslar
KAYAALP O. Akılcıl Tedavi Yönünden Tıbbi Farmakoloji. Pelikan. 2018.
Rang H, Dale M, Ritter J, et al. Rang and Dale’s Pharmacology (Ninth ed.). London: Churchill Livingstone Elsevier. 2019.
European Monitoring Centre for Drugs and Drug Addiction. 2018. The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe.https://www.emcdda.europa.eu/topics/pods/benzodiazepines.
European Monitoring Centre for Drugs and Drug Addiction. 2021. New benzodiazepines in Europe – a review. https://www.emcdda.europa.eu/publications/technical-reports/new-benzodiazepines-europe-review_en.
Mehdi T. Benzodiazepines revisited. British Journal of Medical Practitioners. 2012; 5(1), 501.
Moosmann B, Auwärter V. Designer benzodiazepines: Another class of new psychoactive substances. Handbook of Experimental Pharmacology. 2018. 383-410. doi:10.1007/164_2018_154.
Zawilska JB, Wojcieszak J. An expanding world of new psychoactive substances—designer benzodiazepines. [Online] NeuroToxicology. 2019; 73, 8-16. doi:10.1016/j.neuro.2019.02.015.
Orsolini L, Corkery JM, Chiappini S, et al. ‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip Reports. Current Neuropharmacology. 2020; 18, 809-837. doi:10.2174/1570159x18666200110121333.
Mutlu E, Aşicioğlu F. Abuse of prescribed psychoactive drugs. Anadolu Psikiyatri Dergisi. 2020; 21(2), 195-202. doi:10.5455/apd.53469.
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. [Online] Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. 2013. doi:10.1176/appi.books.9780890425596.893619
Gulec G, Kosger F, Essizoglu A. Alcohol and Substance Use Disorders in DSM-5. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry. 2015; 7(4), 448-460. doi:10.5455/cap.20150325081809.
Türkiye Cumhuriyeti Anayasası. 2709 sayılı kanun. 2018. https://www.tbmm.gov.tr/anayasa.htm_2018.pdf.
Türk Ceza Kanunu. 5237 sayılı Türk Ceza Kanunu. 2004. https://www.mevzuat.gov.tr/MevzuatMetin/1.5.5237.pdf.
Katzung BG. Basic & Clinical Pharmacology, Fourteenth Edition. Basic and Clinical Pharmacology. 2018.
Gilman AG. Goodman & Gilman’s The Pharmacological Basis of Therapeutics Thirteenth Edition. Mc Graw Hill Education. 2018.
DRUGDEX. [Online] IBM Micromedex [Electronic version]; www.micromedexsolutions.com.
Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: A future for subtype-selective GABAA receptor modulators?. [Online] Advances in Pharmacological Sciences. 2012. doi:10.1155/2012/416864
Qriouet Z, Qmichou Z, Bouchoutrouch N, et al. Analytical Methods Used for the Detection and Quantification of Benzodiazepines. [Online] Journal of Analytical Methods in Chemistry. 2019. doi:10.1155/2019/2035492.
Nasir Uddin M. An Overview on Total Analytical Methods for the Detection of 1,4-Benzodiazepines. Pharmaceutica Analytica Acta. 2014; 5(6), 1000303. doi:10.4172/2153-2435.1000303..
Moeller KE, Lee KC, Kissack JC. Urine drug screening: Practical guide for clinicians. [Online] Mayo Clinic Proceedings. 2008;83(1):66-76. doi:10.4065/83.1.66.
Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: A review. [Online] Journal of Analytical Toxicology. 2014;38:387–396. doi:10.1093/jat/bku075.
Fraser AD, Howell P. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. Journal of Analytical Toxicology. 1998; 22(1), 50-54. doi:10.1093/jat/22.1.50.
Nasky KM, Cowan GL, Knittel DR. False-positive urine screening for benzodiazepines: An association with sertraline? A two-year retrospective chart analysis. Psychiatry. 2009;6(7):36–39.
Blank A, Hellstern V, Schuster D, et al. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clinical Infectious Diseases. 2009; 48:1787–9. doi:10.1086/599109.
Gunn, NI. Negative Urine Drug Screen in a Patient with Chronic Benzodiazepine Use. Proceedings of UCLA Healthcare, 20. 2016.
Beck O, Stephanson N, Sandqvist S, et al. Detection of drugs of abuse in exhaled breath using a device for rapid collection: Comparison with plasma, urine and self-reporting in 47 drug users. Journal of Breath Research. 2013; 7(2), 026006. doi:10.1088/1752-7155/7/2/026006.
Vindenes V, Lund HME, Andresen W, et al. Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers. Forensic Science International. 2012; 165–171. doi:10.1016/j.forsciint.2012.01.001
Lee S, Han E, In S, et al. Determination of illegally abused sedative-hypnotics in hair samples from drug offenders. Journal of Analytical Toxicology. 2011; 35(5), 312-315. doi:10.1093/anatox/35.5.312
Marin SJ, Merrell M, McMillin GA. Drugs of abuse detection in meconium: A comparison between ELISA and biochip microarray. Journal of Analytical Toxicology. 2011; 35(1), 40-45. doi:10.1093/anatox/35.1.40
Mayo Clinic Laboratories. Benzodiazepines. https://www.mayocliniclabs.com /test-info/drug-book/benzodiazepines.html
U.S Food & Drug Administration (FDA). 2020. Benzodiazepine Drug Class: Drug Safety Communication - Boxed Warning Updated to Improve Safe Use. https://www.fda.gov/safety/medical-product-safety-information/benzodiazepine-drug-class-drug-safety-communication-boxed-warning-updated-improve-safe-use.
S. Anna Gandra S, D Almeida AL, M. Teixeira Z. Benzodiazepines Dependence: Addiction to Legally Prescribed Substances. Journal of Forensic Psychology. 2019; 4:149.doi:10.35248/2475-319x.19.4.149.
Özgen A, Birsöz S. Benzodiazepinler “Yararlanım ve Kötü Kullanım Ölçütleri. Bağımlılık Dergisi, 1(2), 89-94. 2000.
Tae Woo Park, MD Ms. Benzodiazepine use disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis - UpToDate. uptodate.
Association AP, others. Diagnostic and Statistical Manual of Mental Disorders. 4th text revision ed. Washington, DC: American Psychiatric Association. 2000.
Gündüz N. 2019. Yasa dışı madde kullanımlarına adli psikiyatrik yaklaşımlar. Naile Esra Saka (Ed). Adli Tıp ve Adli Bilimlerde Klinik Uygulamalara Bakış içinde (s. 295 – 309). Akademisyen Kitabevi.
Çöpür M, Eryılmaz A, Çakmak D. Alkol, madde kullanımı ve yasal sorunlar. Okmeydanı Tıp Dergisi, 2014; 30(Ek sayı 2), 84-88. doi:10.5222/otd.supp2.2014.084.
Denetimli Serbestlik Hizmetleri Kanunu. 5402 sayılı Denetimli Serbestlik Hizmetleri Kanunu. 2005. https://www.mevzuat.gov.tr/MevzuatMetin/1.5.5402.pdf.
O’Connell CW, Sadler CA, Tolia VM, et al. Overdose of etizolam: The abuse and rise of a benzodiazepine analog. [Online] Annals of Emergency Medicine. 2015; 65(4),465-466. doi:10.1016/j.annemergmed.2014.12.019.
Pettersson Bergstrand M, Helander A, Hansson T, et al. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Testing and Analysis. 2017; 9, 640–645 doi:10.1002/dta.2003.
Švidrnoch M, Boráňová B, Tomková J, et al. Simultaneous determination of designer benzodiazepines in human serum using non-aqueous capillary electrophoresis – Tandem mass spectrometry with successive multiple ionic – Polymer layer coated capillary. Talanta. 2018;176, 69–76. doi:10.1016/j.talanta.2017.08.010.
Pettersson Bergstrand M, Beck O, Helander A. Urine analysis of 28 designer benzodiazepines by liquid chromatography–high-resolution mass spectrometry. Clinical Mass Spectrometry. 2018; 10, 25–32. doi:10.1016/j.clinms.2018.08.004.
Andersson M, Kjellgren A. The slippery slope of flubromazolam: Experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. NAD Nordic Studies on Alcohol and Drugs. 2017; 34(3), 217-229. doi:10.1177/1455072517706304.